Charles P Taylor

List of Publications by Year
in descending order

39 papers	5,821 citations	147801 31 h-index	315739 38 g-index
40 all docs	40 docs citations	40 times ranked	3919 citing authors

#	Article	IF	Citations
1	Analgesia with Gabapentin and Pregabalin May Involve <i>N</i>-Methyl-d-Aspartate Receptors, Neurexins, and Thrombospondins. Journal of Pharmacology and Experimental Therapeutics, 2020, 374, 161-174.	2.5	32
2	The diverse therapeutic actions of pregabalin: is a single mechanism responsible for several pharmacological activities?. Trends in Pharmacological Sciences, 2013, 34, 332-339.	8.7	251
3	Pregabalin is a potent and selective ligand for Î±2Î´-1 and Î±2Î´-2 calcium channel subunits. European Journal of Pharmacology, 2011, 667, 80-90.	3.5	116
4	Anxiolytic-Like Activity of Pregabalin in the Vogel Conflict Test in Î±₂Î´-1 (R217A) and Î±₂Î´-2 (R279A) Mouse Mutants. Journal of Pharmacology and Experimental Therapeutics, 2011, 338, 615-621.	2.5	50
5	Central Sensitization and CaVÎ±2Î´ Ligands in Chronic Pain Syndromes: Pathologic Processes and Pharmacologic Effect. Journal of Pain, 2010, 11, 1241-1249.	1.4	73
6	Reply to: How does gabapentin relieve pain? (Marshall Devor). Pain, 2009, 145, 259-261.	4.2	3
7	Oxadiazolone bioisosteres of pregabalin and gabapentin. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 247-250.	2.2	15
8	Anxiolytic profile of pregabalin on elicited hippocampal theta oscillation. Neuropharmacology, 2009, 56, 379-385.	4.1	39
9	Mechanisms of analgesia by gabapentin and pregabalin â€“ Calcium channel Î±2-Î´ [CavÎ±2-Î´] ligands. Pain, 2009, 142, 13-16.	4.2	217
10	Ca2+ channel Î±2Î´ ligands: novel modulators of neurotransmission. Trends in Pharmacological Sciences, 2007, 28, 75-82.	8.7	395
11	Pharmacology and mechanism of action of pregabalin: The calcium channel Î±2â€“Î´ (alpha2â€“delta) subunit as a target for antiepileptic drug discovery. Epilepsy Research, 2007, 73, 137-150.	1.6	492
12	Activity profile of pregabalin in rodent models of epilepsy and ataxia. Epilepsy Research, 2006, 68, 189-205.	1.6	77
13	Carboxylate bioisosteres of gabapentin. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 2333-2336.	2.2	22
14	Pregabalin action at a model synapse: Binding to presynaptic calcium channel Î±2-Î´Âsubunit reduces neurotransmission in mice. European Journal of Pharmacology, 2006, 553, 82-88.	3.5	59
15	Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: An ex vivo autoradiographic study in alpha2-delta type 1 genetically modified mice. Brain Research, 2006, 1075, 68-80.	2.2	142
16	Pregabalin Reduces the Release of Synaptic Vesicles from Cultured Hippocampal Neurons. Molecular Pharmacology, 2006, 70, 467-476.	2.3	96
17	Novel Cyclopropyl Î²-Amino Acid Analogues of Pregabalin and Gabapentin That Target the Î±₂-Î´ Protein. Journal of Medicinal Chemistry, 2005, 48, 3026-3035.	6.4	43
18	Structureâˆ’Activity Relationships of Pregabalin and Analogues That Target the Î±2-Î´ Protein. Journal of Medicinal Chemistry, 2005, 48, 2294-2307.	6.4	197

#	Article	IF	Citations
19	Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain, 2003, 105, 133-141.	4.2	290
20	Antiepileptic drugs for treatment of neuropathic pain. , 2002, , 211-232.		2
21	The effects of gabapentin in the rat hippocampus are mimicked by two structural analogs, but not by nimodipine. Epilepsy Research, 2000, 41, 155-162.	1.6	17
22	Rodent Model of Chronic Central Pain After Spinal Cord Contusion Injury and Effects of Gabapentin. Journal of Neurotrauma, 2000, 17, 1205-1217.	3.4	151
23	A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Research, 1998, 29, 233-249.	1.6	742
24	Phenytoin and Fosphenytoin. , 1997, , 253-256.		0
25	Sodium Channels and Therapy of Central Nervous System Diseases. Advances in Pharmacology, 1997, , 47-98.	2.0	55
26	Phenytoin pretreatment prevents hypoxic-ischemic brain damage in neonatal rats. Developmental Brain Research, 1996, 95, 169-175.	1.7	30
27	Benefit of vitamin E, riluzole, and gababapentin in a transgenic model of familial amyotrophic lateral sclerosis. Annals of Neurology, 1996, 39, 147-157.	5.3	658
28	Effects of anticonvulsant drug gabapentin on the enzymes in metabolic pathways of glutamate and GABA. Epilepsy Research, 1995, 22, 1-11.	1.6	147
29	Hippocampal slices: glutamate overflow and cellular damage from ischemia are reduced by sodium-channel blockade. Journal of Neuroscience Methods, 1995, 59, 121-128.	2.5	97
30	Na+ channels as targets for neuroprotective drugs. Trends in Pharmacological Sciences, 1995, 16, 309-316.	8.7	233
31	Enantioselective synthesis of PD144723: a potent stereospecific anticonvulsant.. Bioorganic and Medicinal Chemistry Letters, 1994, 4, 823-826.	2.2	82
32	Damage from oxygen and glucose deprivation in hippocampal slices is prevented by tetrodotoxin, lidocaine and phenytoin without blockade of action potentials. Brain Research, 1994, 664, 167-177.	2.2	105
33	Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin. Epilepsy Research, 1993, 14, 11-15.	1.6	133
34	Gabapentin anticonvulsant action in rats: disequilibrium with peak drug concentrations in plasma and brain microdialysate. Epilepsy Research, 1993, 16, 175-181.	1.6	117
35	Na+ currents that fail to inactivate. Trends in Neurosciences, 1993, 16, 455-460.	8.6	157
36	3-Alkyl GABA and 3-alkylglutamic acid analogues: two new classes of anticonvulsant agents. Epilepsy Research, 1992, 11, 103-110.	1.6	91

#	Article	IF	Citations
37	Gabapentin increases aminooxyacetic acid-induced GABA accumulation in several regions of rat brain. Neuroscience Letters, 1991, 128, 150-154.	2.1	182
38	Ralitoline (CI-946) and CI-953 block sustained repetitive sodium action potentials in cultured mouse spinal cord neurons and displace batrachotoxinin A 20-Î±-benzoate binding in vitro. Epilepsy Research, 1991, 8, 197-203.	1.6	16
39	3-Alkyl-4-aminobutyric acids: the first class of anticonvulsant agents that activates L-glutamic acid decarboxylase. Journal of Medicinal Chemistry, 1991, 34, 2295-2298.	6.4	95